Supplements for high-cholesterol patients

Evidence-based adjuncts for adults with elevated LDL or apolipoprotein B, alongside lifestyle changes and statin therapy where indicated.

The cardiovascular evidence pyramid for cholesterol is unambiguous: statins, ezetimibe, and (in selected patients) PCSK9 inhibitors are what reduce events. Supplements move LDL modestly — single-digit to mid-teens percent reductions — and stack additively with diet and exercise. The two with the strongest evidence are soluble-fibre supplements (psyllium, oat beta-glucan) and plant sterols/stanols. Red yeast rice contains naturally-occurring monacolin K (essentially low-dose lovastatin) — it works, but it has the same side effects and drug interactions as a statin, and product quality varies dramatically. Niacin and red yeast rice are not statin substitutes.

Psyllium husk (soluble fibre)

FDA-recognised cholesterol claim · LDL ↓ 5–10%

Tier 1

Oat beta-glucan

FDA cholesterol claim · LDL ↓ 5–7%

Tier 2

Plant sterols and stanols

LDL ↓ 8–12% at 2 g/day

Tier 1

Omega-3 EPA/DHA

Triglycerides ↓ 20–30% at 2–4 g/day · CV adjunct

Tier 1

Bergamot polyphenol extract

LDL ↓ ~10% in small trials · Tier 2

Tier 2

Berberine

LDL ↓ 10–15% · Drug interactions watch

Tier 2

Niacin (high-dose)

Statin-era trials negative on outcomes · Tier 3

Tier 3

Red yeast rice (monacolin K)

Effectively low-dose statin · Quality varies

Tier 3

The high-cholesterol stack — rationale by ingredient

Soluble fibre — psyllium husk 10 g/day (or oat beta-glucan 3 g/day)

The FDA recognises a cholesterol-lowering health claim for psyllium and oat beta-glucan; the trial base is among the strongest in supplements. Expected LDL reduction is 5–10% at adequate dose, additive to statin therapy. Take with a full glass of water, separated from other medications by 1–2 hours.

Plant sterols / stanols 2 g/day

Compete with dietary cholesterol for absorption. The 2 g/day dose (from fortified spreads or capsules) reduces LDL by 8–12% on top of dietary measures. Stack additively with statin and fibre.

Omega-3 EPA/DHA 2–4 g/day

The primary indication is triglyceride reduction (20–30% at high doses). The icosapent-ethyl REDUCE-IT trial showed cardiovascular event reduction at 4 g/day in selected high-risk patients; mixed omega-3 (STRENGTH trial) was negative. EPA-predominant products at 2–4 g/day are reasonable in patients with high triglycerides.

Berberine 500 mg twice daily (cautious selection)

Modest LDL reduction (10–15%) in trials. Watch for drug interactions — berberine inhibits CYP3A4 and can raise levels of statins, calcium-channel blockers, and other CYP3A4 substrates. Not first-line; consider only after standard options.

Bergamot polyphenol extract 500–1000 mg/day

Small Italian trials show LDL reduction of approximately 10% at standardised extracts. Trial quality is modest. Reasonable as a polyphenol adjunct in patients seeking non-statin options after standard supplements.

What to skip — or use cautiously

Red yeast rice — contains naturally-occurring monacolin K (lovastatin). It works like a low-dose statin and has the same risks: muscle pain, liver effects, drug interactions. Product quality is highly variable — some contain almost no active and others contain doses comparable to prescription statins. If you wouldn't tolerate a statin, you won't tolerate red yeast rice; if you would, a prescription statin is more predictable and often cheaper.
Niacin in flush-free (inositol hexanicotinate) form — does not have the lipid effects of true niacin.
High-dose niacin — the statin-era AIM-HIGH and HPS2-THRIVE trials did not show cardiovascular benefit despite lipid changes; routine use is no longer recommended.
Garlic supplements for cholesterol — modest historic signal that has largely disappeared in modern trials.
Policosanol — Cuban trials were positive but have not replicated in independent studies.
Krill oil at typical consumer doses — under-doses EPA/DHA relative to the cost; capsule for capsule it's much less omega-3 than fish or algal oil.

Educational reference, not medical advice. Discuss any supplement change with a qualified clinician — particularly if you take a statin, are considering one, or have a personal or family history of cardiovascular disease. Supplements complement lifestyle and (where indicated) statin therapy; they do not replace either.

Sources

Jovanovski E, et al. Effect of psyllium on LDL cholesterol: a meta-analysis. Am J Clin Nutr. 2018;108(5):922–932. PMID: 30239559
Ho HV, et al. The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. Br J Nutr. 2016;116(8):1369–1382. PMID: 27724985
Ras RT, et al. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112(2):214–219. PMID: 24780090
Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22. PMID: 30415628
Cohen PA, et al. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol. 2017;24(13):1431–1434. PMID: 28618907
HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212. PMID: 25014686